
BUD · NYSE
Expected to report Feb 11, 2027 — estimated from last year’s reporting date.
Consensus is $1.13 EPS for Dec 2026 across 6 estimates, ranging $1.06 to $1.24.
The supplied quarter headline was a clear EPS beat: 1.21 against 1.14 consensus, or 6.14%. The detailed release, however, presents nine-month results through 30 September rather than standalone third-quarter results. It reports nine-month basic EPS of $4.01 and underlying EPS of $3.40, up from $2.46 and $2.78, respectively, a year earlier. The materials do not provide a standalone third-quarter year-on-year comparison or a prior-quarter comparison, so those trends cannot be quantified here.
The nine-month picture combines solid underlying growth with a meaningful currency tailwind and a large finance-line swing. Revenue increased 10.7% to $48.4 billion, but grew 5.4% excluding currency, acquisitions and disposals, classification changes and Argentina hyperinflation effects. Normalized EBITDA rose 10.0% to $17.3 billion, or 5.0% on that adjusted basis, while operating profit increased 12.3% to $13.2 billion. Volumes were almost flat: strength in Middle Americas offset declines in North America and Asia Pacific. Net finance expense dropped by $2.0 billion, principally reflecting a reversal in derivative mark-to-market results; this helped lift period profit to $9.0 billion from $6.1 billion. The release also points to higher commercial investment and cost pressures, with adjusted SG&A up 5.7% and cost per hectoliter up 2.3%.